18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease.
This bicentric study assessed retrospectively the usefulness of 18 F-FDG-PET in the staging of 31 patients with lymphocyte-predominant Hodgkin's disease (LPHD). FDG-PET and conventional explorations (CE) were performed for initial disease (n=25) or recurrence (n= 6). All the 68 involved sites were detected by PET including 5 extra-nodal lesions. Only 43 nodal sites (68%) and one splenic focus were detected by CE. PET changed staging in 9 patients (7 upstaged, 2 downstaged) and radiation fields in 3 patients. These results showed the potential role of PET in the staging of LPHD.
Ansquer
Catherine
C
Département de Médecine Nucléaire, CHU de Nantes, Nantes, France.
Hervouët
Thomas
T
Devillers
Anne
A
de Guibert
Sophie
S
Gastinne
Thomas
T
Le Gouill
Steven
S
Garin
Etienne
E
Moreau
Anne
A
Kraeber-Bodéré
Françoise
F
Lamy
Thierry
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000473:pathology*; D006801:Humans; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000494:pharmacology*; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18